BioLargo, Inc. · OTC:BLGO
BioLargo — Corporate Update (September 2026)
24 slides from BioLargo's corporate update, Sep 14, 2026
Slide 1: Shareholder Town Hall
cee r( BioLargo Shareholder Town Hall = Thursday, September 10, 2026 - 1:00 p.m. Pacific / 4:00 p.m. Eastern Dennis P, Calvert, President and Chief Executive Officer FORWARD-LOOKING STATEMENTS
Slide 2: BioLargo does not manufacture products. BioLargo manufactures companies.
BioLargo does not manufacture products. BioLargo manufactures companies.
Slide 3: It works the same way every time
It works the same way every time 2 Lt: ] Atechnology Something Carried until Somebody thatisoneof measurably somebody else funds akind different outside pays the scale to enter De-risking is the product. Small amounts of our capital, into positions that other people's capital makes large.
Slide 4: Seven companies, each separately incorporated
Seven companies. Each separately incorporated to capitalize and monetize one-of-a-kind value comPANY OWNERSHIP ROYALTY TO THE PARENT NOTE Clyra Medical 48.1% 6% ofnet revenue —_Meston Control“ Wound & BioLargo CPG 78% 5% ofnet revente consumer products ONM Environmental 100% Industrial O#or Control
Slide 5: Examples
Examples Incubation Tu’ Nipi Proving up BETI (Cellinity) Regulatory BEST (PFAS/Water) Scaling through partnership Clyra Medical BioLargo CPG 5 Exit Where it all pays off
Slide 6: What the business model predicts
STEPS — o— cmp What the business model predicts WHERE CAPITAL 1S CONSUMED WHERE VALUE IS REALIZED Steps 1, 2 and 3 Step 4 That is the cost side of the model showing up before the value side does.
Slide 7: The Q2 2026 quarter
The Q2 2026 quarter $2.78M su2M $1.25M 02 2025 3 2026 02 2026 The year-over-year decline is the Pooph business we exited and will re-enter in Q4 2026. Q2 2025 included $1.6 million from such revenues even as were exiting the business. +12% Quarter over quarter Qi to Q2 2026 +26% Six months, excludin
Slide 8: Where the loss sits, and how Clyra funded it
Where the loss sits, and how Clyra funded it CLYRA MEDICAL, THIS HALF THE SIX-MONTH NET LOSS OF $7.40 % of our revenue I 6.5% $2.35M $5.05M Belongs to outside Attributable to BioLargo's | 559% of our operating loss investors in our shareholders. subsidiaries, the large majority of it Clyra's. We bui
Slide 9: Who funded it
Who funded it $3.40M $487K $650K Raised inside Clyra Medical, from Raised inside the battery company Ralsed from BioLargo stock investors who chose Clyra 8 6 ry Y; of what we raised this half was raised inside 0 the businesses building value. ‘And what makes it possible: BioLargo guarantees $4,295,0
Slide 10: Cost discipline, and the two hits
Cost discipline, and the two hits WHAT CAME DOWN TWO THINGS WENT AGAINST US =27% lower corporate overhead ‘The Pooph license, revoked in September We lost the revenue. We kept the -13% — lowersalaries proof... and the opportunity ‘The Clyra launch, longer than planned +16% consolidated SG&A. Profess
Slide 11: The battery: we sell factories, not batteries
CAPITAL AS THE BARRIER The battery: we sell factories, not batteries ‘THE BARRIER A factory costs several times what this entire company is worth. ‘That barrier is real if you are trying to carry it yourself. THE ANSWER. We are not trying to carry it. That is the whole strategy. We license the techn
Slide 12: Cellinity: the technology, the demand, and how it scales
CAPITAL AS THE BARRIER Cellinity: the technology, the demand, and how it scales One ofa kind technology, squarely in the US national strategic interest Four macro trends driving adoption Demand Supply chain Degradation Ownership &B Share the wealth, and the leverage is extraordinary 4 No project is
Slide 13: Clyra: three channels, all executed
CHANNEL ACCESS AS THE BARRIER Clyra: three channels, all executed Wound & Burn Care An FDA 510(k) cleared product can still never reach a patient. But not ours! Here the channel is the barrier, not the technology. Advanced Solution Al-Hikma FZCO Wound clinics International THOSE THREE CHANNELS REACH
Slide 14: Clyra Update
Clyra Update WHAT EXISTS ‘+ ViaCLYR, FDA 510(k) cleared, on the patented Clyrasept copper-iodine complex ‘+ Fourteen full-time employees ‘+ Board and medical leadership from Duke and Edwards Lifesciences WHAT GOT DONE THIS YEAR ‘+ First revenue from the sale of ViaCLYR, $154,000 in the half ‘+ Manuf
Slide 15: BEST (PFAS/Water Treatment)
BEST (PFAS/Water Treatment) c .. * Ad pl leted pilot studi Six months of continuous Fle reer aael ee * An MOU with Aquatech on manufacturing operation scale and worldwide delivery * Two commercial pilots proposed, with Garrett County and a new customer + Significant proof of claim in leachate An ope
Slide 16: What changed in PFAS regulation, and what did not
REGULATIONS ARE THE BARRIER What changed in PFAS regulation, and what did not THE NOISE, AND IT IS | | WHAT HAS NOT A REAL HEADWIND CHANGED AND THE REQUIREMENTS ARE NOT RECEDING. THEY ARE SPREADING. Industrial Shorter-chain Wastewater Landfill leachate pret po The drinking water rule was never the w
Slide 17: Tu Nipi: The Power of Strategic Relationships
Tu Nipi: The Power of Strategic Relationships ‘THE PROBLEM IT EXISTS TO SOLVE 1.8 billion cubic meters of tailings and mine water held in Alberta. ‘That may be the largest volume of liquid industrial waste on the planet, and there is still no approved way to treat it and put it back. WHAT GOT DONE E
Slide 18: BioLargo CPG: the proof is already paid for
THE BARRIER IS PROOF BioLargo CPG: the proof is already paid for $125,000,000 of pet-care sales under the Pooph brand, built on our CupriDyne technology. That was not our revenue. We earned a manufacturing margin and a 6% royalty on somebody else's brand. SO HERE IS WHAT THE POOPH EPISODE ACTUALLY W
Slide 19: BioLargo Engineering: Supporting Company Development
BioLargo Engineering: Supporting Company Development susan szasm $574K, up 46% this half $1.02 shows up as revenue at all, because it is eliminated in AND IT PRODUCES DEAL FLOW Outside revenue, on one consistent basis. The 2026 bar is the HidGoRcTESIORLLG eM igh on be aac eae $1.2 million contract i
Slide 20: Engagements that Validate
WHERE THE CONFIDENCE COMES FROM Engagements that Validate Every organization here ran its own diligence and committed something it cannot easily take back: money, a contract, a reputation, or a regulatory process. REGULATORS AND AGENCIES EPA and the State of New Jersey Testing the AEC in municipal s
Slide 21: Two Subsidiaries Alone Support a Valuation of ~$70M
Two Subsidiaries Alone Support a Valuation of ~$70M ROW WHAT WE OWN BASIS VALUE to BioLargo 1 48.1% of Clyra Medical 2 78% of BloLargo CPG 3 100% of ONM Environmental 4 100% of the water business 5 93.8% of the battery company 6 70% of BioLargo Engineering 7 a9% of Tu Ni 8 Theroyalties 9 The guarant
Slide 22: The Arithmetic
The Arithmetic Clyra Medical $35.6M to $41.0M BETI (Cellinity) $33.7M Those two rows together $69.3M to $74.7M Market capitalization About $35M Two of our seven businesses, valued usit ig only figures already in our public filings, are worth roughly twice this entire company.
Slide 23: What changes the perception
What changes the perception Every one of these converts something the market cannot see into something it can. Consumer products goes live in October, with revenue under our own brand GB 4 first municipal contract for water EBB A financing of a battery factory deal GB cive's channels converting to p
Slide 24: What to watch over the next six to nine months
What to watch over the next six to nine months Updated from the list we published on August 17. Consumer relaunch live in October, with first sales under ‘our own brand The minerals design conclided, and whether it leads to the larger facility pp 4I-Hikma and spartan converted from to BB purchase or